{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:12:52Z","timestamp":1777554772471,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract: Background:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Tolerability issues including acne, nausea, and headache have been reported with Janus kinase (JAK) inhibitors for moderate-to-severe atopic dermatitis (AD).\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Objectives:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>To report outcomes of tolerability adverse events (AEs) for baricitinib, a JAK1\/JAK2 inhibitor, in patients with moderate-to-severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Methods:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>Acne, headache, and gastrointestinal AEs are reported from placebo-controlled and long-term extensions of pooled data in the baricitinib AD clinical trial program. Proportions of patients with AEs, incidence rates (IRs)\/100 patient-years at risk, and median time to onset\/duration of AEs were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Results:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>In 2531 patients treated with baricitinib, most AEs were mild to moderate in severity. Headache was the most common AE of tolerability (median of 14\u201326 days after first dose of baricitinib, lasting \u22643 days). IRs of acne were &lt;5 in any group lasting up to a median of 90 days with no severe AEs. Diarrhea was the most common gastrointestinal AE, lasting a median of \u22647 days. There were few study drug interruptions (n\u2009=\u20096) and permanent discontinuations (n\u2009=\u20095) for tolerability AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Conclusions:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>For the AEs of tolerability analyzed, baricitinib appears to be well tolerated. Overall, the frequency of these AEs in patients being treated for moderate-to-severe AD was low with few leading to study drug interruption or permanent discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:underline>Clinical Trial Registration number:<\/jats:underline>\n                    <\/jats:title>\n                    <jats:p>NCT02576938; NCT03334396; NCT03334422; NCT03428100; NCT03435081; NCT03733301; NCT03334435; NCT03559270<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/derm.2022.0027","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T09:07:36Z","timestamp":1675760856000},"page":"308-314","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Pooled Analysis of Baricitinib Tolerability in Patients with Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events from 8 Clinical Trials"],"prefix":"10.1177","volume":"34","author":[{"given":"Andreas","family":"Wollenberg","sequence":"first","affiliation":[{"name":"From the,  Department of Dermatology and Allergy University Hospital, Ludwig Maximilian University of Munich, Munich, Germany."},{"name":"Department of Dermatology, Free University Brussels, University Hospital Brussels, Brussels, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Simpson","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University, Portland, Oregon, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Brinker","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kyoto Prefectural University of Medicine, Kyoto, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Rueda","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Issa","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan","family":"Feely","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."},{"name":"Icahn School of Medicine, Mount Sinai, New York, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Alexis","sequence":"additional","affiliation":[{"name":"Weill Cornell Dermatology, New York, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.032"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.010"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.022"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18345"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.018"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_3_2_11_2","first-page":"1333","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"56","author":"Reich K","year":"2021","unstructured":"Reich K, , Kabashima K, , Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol, 2021; 56:1333\u20131343.","journal-title":"JAMA Dermatol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.028"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21630"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00602-x"},{"key":"e_1_3_2_16_2","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry E9 Statistical Principles for Clinical Trials. 1998. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e9-statistical-principles-clinical-trials. Accessed June21 2022."},{"key":"e_1_3_2_17_2","first-page":"1","article-title":"Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials","volume":"22","author":"Reich K","year":"2020","unstructured":"Reich K, , DeLozier AM, , Nunes FP, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat, 2020; 22:1\u201310. doi: 10.1080\/09546634.2020.1839008.","journal-title":"J Dermatolog Treat"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17278"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/derm.2022.0027","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2022.0027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/derm.2022.0027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:06:47Z","timestamp":1777399607000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/derm.2022.0027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8,1]]}},"alternative-id":["10.1089\/derm.2022.0027"],"URL":"https:\/\/doi.org\/10.1089\/derm.2022.0027","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}